|
ABOUT COMPANY
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
|
EARNINGS
Gross Profit (TTM): 152000
Market Capitalization: 2715917000
Operating Margin (TTM): -76.85
PE Ratio: None
PEG Ratio: 0
Profit Margin: 0
Revenue Per Share (TTM): 0.034
Revenue (TTM): 4406000
Quarterly Earnings Growth YOY: 0
Quarterly Revenue Growth YOY: 52.42
Trailing PE: -
|
DIVIDENDS
Diluted EPS (TTM): -2.636
Dividend Date: None
Dividend Per Share: None
Dividend Yield: 0%
EBITDA: -158616992
ExDividend Date: None
Forward Annual Dividend Rate:
Forward Annual Dividend Yield:
|